Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 16, 2021, details the results of the 2021 Annual Meeting of Stockholders for Cocrystal Pharma, Inc. The meeting was held to vote on corporate governance matters, including board elections, auditor ratification, and amendments to the company's charter and equity plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders approved several key proposals at the Annual Meeting:
- Board Elections: Five directors were elected for one-year terms: Dr. Phillip Frost, Mr. Roger Kornberg, Mr. Steven Rubin, Dr. Anthony Japour, and Mr. Richard C. Pfenniger, Jr.
- Auditor Ratification: Stockholders ratified the appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Capital Structure Amendment: The authorized number of common stock shares was increased from 100,000,000 to 150,000,000 shares.
- Equity Plan Amendment: The number of shares authorized for issuance under the 2015 Equity Incentive Plan was increased from 5,000,000 to 10,000,000 shares.
- Executive Compensation: Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- Voting Frequency: Stockholders voted on the frequency of executive compensation votes, with a split preference between one-year and three-year intervals.
Proposal 7, regarding the adjournment of the meeting, was rendered moot as sufficient votes were cast to approve all other proposals.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a record of the completed shareholder vote.
Key Facts for Investor Verification
- Verify the impact of the increased authorized share count (150 million) on potential future dilution.
- Confirm the details of the expanded 2015 Equity Incentive Plan (10 million shares) and its implications for employee compensation.
- Review the definitive proxy statement filed on April 26, 2021, for detailed biographies of the newly elected directors and specific compensation metrics.
- Note the significant number of broker non-votes (14,538,824) recorded for several proposals, indicating shares held in street name where brokers lacked discretionary voting power.